Full Press Release Details
dupixent dupilumab approved in the u s as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria csu.
REGN
dupixent dupilumab approved in the u s as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria csu
Key Takeaway: dupixent dupilumab approved in the u s as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria csu